

Boehringer Ingelheim–Industry Supported Symposium

IASLC 19th World Conference on Lung Cancer

OVERCOMING CHALLENGES IN THORACIC MALIGNANCIES: EXPERT INSIGHTS

Chair: David Gandara

Monday, 24 September, 18:00 – 19:30

NORTH BUILDING, ROOM 106
METRO TORONTO CONVENTION CENTRE
TORONTO, CANADA



This program was approved by the IASLC 19th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 19th World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC.

It is our pleasure to invite you to attend:

OVERCOMING CHALLENGES IN THORACIC MALIGNANCIES: EXPERT INSIGHTS

At this symposium, an international faculty of experts will discuss clinical considerations for sequencing EGFR TKIs, for preventing and managing brain metastases in patients with *EGFR* mutation-positive NSCLC, and for maximising the potential of TKIs for SqCC of the lung. These treatment considerations in adenocarcinoma and in SqCC of the lung will also be further explored in a panel discussion.

18:00 – 18:05

Meeting welcome and introductions

[David Gandara](#)

18:05 – 18:20

Clinical considerations in *EGFR* mutation-positive NSCLC: does treatment sequence matter?

[Barbara Melosky](#)

18:20 – 18:35

Clinical considerations in *EGFR* mutation-positive NSCLC: the challenge of preventing and managing brain metastases

[Noemi Reguart](#)

18:35 – 18:50

Panel discussion: treatment considerations in adenocarcinoma

All Faculty; moderated by [David Gandara](#)

18:50 – 19:10

Maximising the clinical potential of TKIs for patients with squamous NSCLC

[David Gandara](#)

19:10 – 19:25

Panel discussion: treatment considerations in SqCC of the lung

All Faculty; moderated by [David Gandara](#)

19:25 – 19:30

Meeting close

[David Gandara](#)

